Ascochlorin suppresses TGF-β1-induced PAI-1 expression through the inhibition of phospho-EGFR in rat kidney fibroblast cells

Molecular Biology Reports

Volumn 39, Issue 4, 2012, Pages 4597-4603

  Cho, Hyun Ji ^a   Kang, Jeong Han ^a   Jeong, Ji Hak ^a   Jeong, Yun Jeong ^a   Park, Kwan Kyu ^a   Park, Yoon Yub ^a   Moon, Yong Suk ^a   Kim, Hong Tae ^a   Chung, Il Kyung ^a   Kim, Cheorl Ho ^b   Chang, Hyeun Wook ^c   Chang, Young Chae ^a  

^a Catholic University of Daegu   (South Korea)

^b Sungkyunkwan University   (South Korea)

^c Yeungnam University   (South Korea)

Author keywords

Ascochlorin; Epidermal growth factor receptor; Fibros; Matrix metalloproteinase; Plasminogen activator inhibitor 1

Indexed keywords

ANTIFIBROTIC AGENT; ASCOCHLORIN; COLLAGEN TYPE 1; GELATINASE B; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; MESSENGER RNA; PLASMINOGEN ACTIVATOR INHIBITOR 1; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR; ALKENE; EPIDERMAL GROWTH FACTOR RECEPTOR; PHENOL DERIVATIVE; PROTEIN KINASE INHIBITOR; PROTEINASE INHIBITOR;

ANIMAL CELL; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REPRESSION; FIBROBLAST CULTURE; IN VITRO STUDY; NONHUMAN; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; ANIMAL; CELL LINE; CHEMISTRY; CYTOLOGY; DRUG ANTAGONISM; ENZYMOLOGY; FIBROBLAST; GENE EXPRESSION REGULATION; GENETICS; KIDNEY; METABOLISM; PHOSPHORYLATION;

RATTUS;

ALKENES; ANIMALS; CELL LINE; FIBROBLASTS; GENE EXPRESSION REGULATION; KIDNEY; MAP KINASE SIGNALING SYSTEM; MATRIX METALLOPROTEINASE 9; PHENOLS; PHOSPHORYLATION; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEASE INHIBITORS; PROTEIN KINASE INHIBITORS; RATS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA, MESSENGER; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84862999231     PISSN: 03014851     EISSN: 15734978     Source Type: Journal    
DOI: 10.1007/s11033-011-1251-y     Document Type: Article

References (35)

1. Li F, Zeng B, Chai Y, Cai P, Fan C, Cheng T (2009) The linker region of Smad2 mediates TGF-beta-dependent ERK2-induced collagen synthesis. Biochem Biophys Res Commun 386:289-293. doi:10.1016/j.bbrc.2009.05.084
2. Verrecchia F, Mauviel A (2004) TGF-beta and TNF-alpha: antagonistic cytokines controlling type I collagen gene expression. Cell Signal 16:873-880. doi:10.1016/j.cellsig.2004.02.007
3. Dong C, Zhu S, Wang T, Yoon W, Goldschmidt-Clermont PJ (2002) Upregulation of PAI-1 is mediated through TGF-beta/Smad pathway in transplant arteriopathy. J Heart Lung Transplant 21:999-1008. doi:10.1016/S1053-2498(02) 00403-5
4. Cho HJ, Kang JH, Kim T, Park KK, Kim CH, Lee IS, Min KS, Magae J, Nakajima H, Bae YS, Chang YC (2009) Suppression of PAI-1 expression through inhibition of the EGFR-mediated signaling cascade in rat kidney fibroblast by ascofuranone. J Cell Biochem 107:335-344. doi:10.1002/jcb.22130
5. Shi Y, Massague J (2003) Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 113:685-700. doi: 10.1016/S0092-8674(03)00432-X
6. Tahashi Y, Matsuzaki K, Date M, Yoshida K, Furukawa F, Sugano Y, Matsushita M, Himeno Y, Inagaki Y, Inoue K (2002) Differential regulation of TGF-beta signal in hepatic stellate cells between acute and chronic rat liver injury. Hepatology 35:49-61. doi:10.1053/jhep.2002.30083
7. Verrecchia F, Mauviel A (2002) Transforming growth factor-beta signaling through the Smad pathway: role in extracellular matrix gene expression and regulation. J Invest Dermatol 118:211-215. doi:10.1046/j.1523-1747.2002.01641.x
8. Mulsow JJ, Watson RW, Fitzpatrick JM, O'Connell PR (2005) Transforming growth factor-beta promotes pro-fibrotic behavior by serosal fibroblasts via PKC and ERK1/2 mitogen activated protein kinase cell signaling. Ann Surg 242:880-887. doi: 10.1097/01.sla.0000189606.58343.cd discussion 887-889
9. Hayashida T, Poncelet AC, Hubchak SC, Schnaper HW (1999) TGF-beta1 activates MAP kinase in human mesangial cells: a possible role in collagen expression. Kidney Int 56:1710-1720. doi:10.1046/j.1523-1755.1999.00733.x
10. Hanafusa H, Ninomiya-Tsuji J, Masuyama N, Nishita M, Fujisawa J, Shibuya H, Matsumoto K, Nishida E (1999) Involvement of the p38 mitogen-activated protein kinase pathway in transforming growth factor-beta-induced gene expression. J Biol Chem 274:27161-27167. doi:10.1074/jbc.274.38.27161
11. Lee HB, Ha H (2005) Plasminogen activator inhibitor-1 and diabetic nephropathy. Nephrology (Carlton) 10 Suppl:S11-S13. doi:10.1111/j.1440-1797. 2005.00449.x
12. Rerolle JP, Hertig A, Nguyen G, Sraer JD, Rondeau EP (2000) Plasminogen activator inhibitor type 1 is a potential target in renal fibrogenesis. Kidney Int 58:1841-1850. doi:10.1111/j.15231755.2000.00355.x
13. Providence KM, White LA, Tang J, Gonclaves J, Staiano-Coico L, Higgins PJ (2002) Epithelial monolayer wounding stimulates binding ofUSF-1 to an E-boxmotif in the plasminogen activator inhibitor type 1 gene. J Cell Sci 115:3767-3777. doi:10.1242/jcs.00051
14. Providence KM, Staiano-Coico L, Higgins PJ (2003) A quantifiable in vitro model to assess effects of PAI-1 gene targeting on epithelial cell motility. Methods Mol Med 78:293-303. doi: 10.1385/1-59259-332-1:293
15. Gaedeke J, Noble NA, BorderWA(2005) Curcumin blocks fibrosis in anti-Thy 1 glomerulonephritis through up-regulation of heme oxygenase 1. Kidney Int 68:2042-2049. doi:10.1111/j.1523-1755. 2005.00658.x
16. Sasaki H, Hosokawa T, Sawada M, Ando K (1973) Isolation and structure of ascofuranone and ascofranol, antibiotics with hypolipidemic activity. J Antibiot (Tokyo) 26:676-680
17. Sawada M, Hosokawa T, Okutomi T, Ando K (1973) Hypolipidemic property of ascofuranone. J Antibiot (Tokyo) 26:681-686
18. Hosokawa T, Okutomi T, Sawada M, Ando K, Tamura G (1981) Unusual concentration of urine and prevention of polydipsia by fungal prenylphenols in DOCA hypertensive rats. Eur J Pharmacol 69:429-438. doi:10.1016/0014-2999(81) 90446-5
19. Magae J, Hayasaki J, Matsuda Y, Hotta M, Hosokawa T, Suzuki S, Nagai K, Ando K, Tamura G (1988) Antitumor and antimetastatic activity of an antibiotic, ascofuranone, and activation of phagocytes. J Antibiot (Tokyo) 41:959-965
20. Hosokawa T, Ando K, Tamura G (1985) An ascochlorin derivative, AS-6, reduces insulin resistance in the genetically obese diabetic mouse, db/db. Diabetes 34:267-274
21. Magae J, Suzuki S, Nagai K, Yamasaki M, Ando K, Tamura G (1986) In vitro effects of an antitumor antibiotic, ascofuranone, on the murine immune system. Cancer Res 46:1073-1078
22. Ahn JD, Morishita R, Kaneda Y, Kim HJ, Kim YD, Lee HJ, Lee KU, Park JY, Kim YH, Park KK, Chang YC, Yoon KH, Kwon HS, Park KG, Lee IK (2004) Transcription factor decoy for AP-1 reduces mesangial cell proliferation and extracellular matrix production in vitro and in vivo. Gene Ther 11:916-923. doi: 10.1038/sj.gt.3302236
23. Huang Y, Wongamorntham S, Kasting J, McQuillan D, Owens RT, Yu L, Noble NA, Border W (2006) Renin increases mesangial cell transforming growth factor-beta1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms. Kidney Int 69:105-113. doi:10.1038/sj.ki.5000011
24. Prenzel N, Zwick E, Daub H, Leserer M, Abraham R, Wallasch C, Ullrich A (1999) EGF receptor transactivation by G-proteincoupled receptors requires metalloproteinase cleavage of proHBEGF. Nature 402:884-888. doi:10.1038/47260
25. Lucchesi PA, Sabri A, Belmadani S, Matrougui K (2004) Involvement of metalloproteinases 2/9 in epidermal growth factor receptor transactivation in pressure-induced myogenic tone in mouse mesenteric resistance arteries. Circulation 110:3587-3593. doi:10.1161/01.CIR.0000148780.36121.47
26. Lyon CJ, Hsueh WA (2003) Effect of plasminogen activator inhibitor-1 in diabetes mellitus and cardiovascular disease. Am J Med 115 Suppl 8A:62S-68S. doi:10.1016/j.amjmed.2003.08.014
27. Ohba K, Miyata Y, Kanda S, Koga S, Hayashi T, Kanetake H (2005) Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis. J Urol 174:461-465. doi:10.1097/01.ju.0000165150.46006.92
28. Hosokawa T, Sawada M, Ando K, Tamura G (1981) Alteration of cholesterol metabolism by 4-O-methylascochlorin in rats. Lipids 16:433-438. doi:10.1007/BF02535011
29. Hong S, Park KK, Magae J, Ando K, Lee TS, Kwon TK, Kwak JY, Kim CH, Chang YC (2005) Ascochlorin inhibits matrix metalloproteinase-9 expression by suppressing activator protein-1-mediated gene expression through the ERK1/2 signaling pathway: inhibitory effects of ascochlorin on the invasion of renal carcinoma cells. J Biol Chem 280:25202-25209. doi:10.1074/jbc.M413985200
30. Kang JH, Kim JK, Park WH, Park KK, Lee TS, Magae J, Nakajima H, Kim CH, Chang YC (2007) Ascochlorin suppresses oxLDL-induced MMP-9 expression by inhibiting the MEK/ERK signaling pathway in human THP-1 macrophages. J Cell Biochem 102:506-514. doi:10.1002/jcb.21312
31. Jeong JH, Chang YC Ascochlorin, an isoprenoid antibiotic, induces G1 arrest via downregulation of c-Myc in a p53-independent manner. Biochem Biophys Res Commun 398:68-73. doi: 10.1016/j.bbrc.2010.06.037
32. Jeong JH, Kang SS, Park KK, Chang HW, Magae J, Chang YC p53-independent induction of G1 arrest and p21WAF1/CIP1 expression by ascofuranone, an isoprenoid antibiotic, through downregulation of c-Myc. Mol Cancer Ther 9:2102-2113. doi: 10.1158/1535-7163.MCT-09-1159
33. Dennler S, Itoh S, Vivien D, ten Dijke P, Huet S, Gauthier JM (1998) Direct binding of Smad3 and Smad4 to critical TGF betainducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. EMBO J 17:3091-3100. doi:10.1093/emboj/17.11.3091
34. Samarakoon R, Higgins CE, Higgins SP, Kutz SM, Higgins PJ (2005) Plasminogen activator inhibitor type-1 gene expression and induced migration in TGF-beta1-stimulated smooth muscle cells is pp60(c-src)/MEK-dependent. J Cell Physiol 204:236-246. doi:10.1002/jcp.20279
35. Xu KP, Ding Y, Ling J, Dong Z, Yu FS (2004) Wound-induced HB-EGF ectodomain shedding and EGFR activation in corneal epithelial cells. Invest Ophthalmol Vis Sci 45:813-820. doi: 10.1167/iovs.03-0851